Vanda Pharmaceuticals Inc. dropped 2.28% in after-hours trading. The decline comes amidst individual investors' concerns over U.S. President Donald Trump's tariff announcements, which have sparked fears of a recession. The S&P 500 has fallen 18.9% from its February peak and 12.1% since the tariff announcement, indicating a broader market downturn that may have affected Vanda Pharmaceuticals' stock price.
Comments
No comments yet